Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Report Looks At HIV Prevalence Among Chicago Gay Men
In Chicago, 17.4 percent of gay men are estimated to be HIV-positive, compared with 1.2 percent of the general male population, according to a new report by the Chicago Public Health Department, the Chicago Sun-Times reports. The report is based on data collected from 570 Chicago men through the National HIV Behavioral Surveillance system, and found that half of the men with HIV were unaware they were infected (Thomas, 7/25). "Health officials said Friday, information in the report on HIV infection mark the first time Chicago health officials have used blood-testing to determine infection rates among men," the AP/Chicago Tribune reports. In the past, estimates have relied on interviews with gay and bisexual men, according to Christopher Brown, the Public Health Department assistant commissioner. The report also found that "black men who have sex with other men have double the HIV infection rates of white and Hispanic men," the AP/Tribune reports (7/24).
generic viagra online
Study Demonstrated Once-Daily Vyvanse(R) CII Provided Significant Improvement Of ADHD Symptoms For Children At 13 Hours After Administration
Shire plc announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse® (lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 from the first time point measured (1.5 hours) up to the last time point assessed (13 hours) after administration. In this pediatric analog classroom study, treatment with Vyvanse was associated with significant improvement in behavior and attention in children at each time point measured, with improvement at 13 hours after administration.
News of the day
The Department Of Health And Human Services Teams Up With The White House And The Ad Council To Launch New Fatherhood Public Service Campaign
Just in time for Father"s Day weekend, the Secretary of Health and Human Services Kathleen Sebelius announced a new public service campaign today promoting fatherhood that features a PSA by President Obama. The campaign, sponsored by the department"s Administration for Children and Families and the Advertising Council, can be found at http://www.fatherhood.gov. The public service announcements and supporting campaign materials highlight the critical role fathers play in their children"s lives.
Nutrition

MiCardia® Announces First U.S. Implant

MiCardia® (MiCardia Corporation, Irvine, California) announced the completion of the first U.S. implant of its Dynaplasty® mitral valve repair technology. The surgery was performed last week at Beaumont Hospital, Royal Oak, Michigan. Francis L. Shannon, M.D., who is a partner in SEMCVS and Director of CV Surgical Research and Quality Outcomes at Beaumont, commented, "The MiCardia® device implanted easily and conformed well to the patient"s mitral annulus. The complete D-shaped ring was used to reinforce a complex repair of a flail leaflet segment using minimally invasive techniques. We are excited to be participating in the DYANA Study and believe Dynaplasty® technology will address a major weakness of current devices, namely their inability to deal with changes in valve shape and function after the initial repair procedure." Commenting on the first U.S. site to enter the study, MiCardia® Chief Executive Officer Paul Molloy said, "This is a major milestone for MiCardia® and we are grateful for Dr. Shannon"s expertise in helping develop this technology. The Dynamic Annuloplasty Activation study involves patients from Europe who receive a device capable of activation post-implant and patients from the U.S. who receive a shape memory device that is not capable of activation. MiCardia® received a 510(k) clearance on the non-active version of its Dynaplasty® System in September 2008. Patient data from both the U.S. and Europe will be submitted toward CE Mark of the Company"s Dynaplasty® devices this year. We expect to complete enrollment and submit six month follow up data from the DYANA Study in Q4 of 2009 as a prelude to European commercialization of the world"s first minimally invasive, beating heart valve repair system." MiCardia® is developing Dynaplasty® technology for the treatment of structural heart disease, focusing initially on mitral and tricuspid valve disorders and as a method of interrupting a major element in the onset and progression of Heart Failure. More than 15m people in Europe and the U.S. are in Heart Failure, of which more than 7m suffer from mitral regurgitation. MiCardia® is a privately held company, founded in 2004 and is developing a completely unique treatment technology that will allow minimally invasive late stage adjustment of cardiac anatomy. Surgical, transcutaneous and entirely non-invasive activation platforms are in advanced development. MiCardia


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009